Reported positions
Quarter-end holdings as filed
Explore the full published position list and its source filing. This record excludes the manager’s cash, shorts and non-13(f) assets.
BVF INC/IL
A quarter-end snapshot. Filed up to 45 days later, so this page is not current holdings and never a complete portfolio. what a 13F is — and is not ↓ · methodology §13F ↗
Period
$3.1B
reported valuesum of disclosed values for 2026-03-31; 0 positions carry a NULL value and are excluded from the sum, surfaced here rather than folded away
41
positionsALL retained default holdings for this (filer, period), including NULL-value ones
4
new stakespositions with no comparable holding in the prior quarter (kind new), 2026-03-31
4
exitspositions absent from this quarter's filing after being held last quarter (kind exit), 2026-03-31 — inferred from absence, not a sale record
Position changes — into 2026-03-31
by shares · Δ value · filing link · how changes are classified §Positionposition matched across quarters by exact reported CUSIP over a registry gap — producer-reconciled identity, never a name match identity_reconciled_by_cusip | Changethe reported share count is unchanged across the pair, so the position reads as held rather than as a buy or a sell; only builds before this release inferred a direction from the reported value instead classified_by_value · "exit" = absent this quarter: disposed, delisted, under confidential treatment, or reported instead by an affiliated manager — the filing does not say which · change not classifiable: value undisclosed on one side of the quarter pair, or neither shares nor value can classify it · "no change" = the share count is identical in both quarters; the value moved only with price, so the row is mark-to-market and never an add or a trim (Add / New / Trim / Exit / No change) · "no prior" = this filer has no comparable holdings list for the previous quarter on record — a first filing under this registration, or a quarter reported inside an affiliated manager's filing — so the position is not called a new stake | Δ valuederived by Public Filings from the published aggregate; NULL means the source did not disclose a usable value — never zero | Δ shares | Prev value | Curr value | Prev shares | Curr shares | Flags |
|---|---|---|---|---|---|---|---|---|
MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORDposition key sid:sec:prov:66a515f74f11d5e1caa284d2543264a2 · issuer key cusip6:61559X | trim | +$37.9M | −3,750,000 | $260M | $298M | 19,751,284 | 16,001,284 | |
REVOLUTION MEDICINES INC COMposition key pos:15541 · issuer key iss:1842 | trim | +$10.5M | −500,000 | $267M | $278M | 3,356,782 | 2,856,782 | |
NEKTAR THERAPEUTICS COM NEWposition key sid:sec:prov:8689270ade82a464b05b5b23e79f9006 · issuer key cusip6:640268 | add | +$118M | +1,000,000 | $65.9M | $184M | 1,559,595 | 2,559,595 | |
STRUCTURE THERAPEUTICS INC SPONSORED ADSposition key sid:sec:prov:862b191ccb923fc424f39385b48ce4f8 · issuer key cusip6:86366E | trim | −$75.2M | −19,664 | $242M | $167M | 3,479,022 | 3,459,358 | |
MIRUM PHARMACEUTICALS INC COMposition key pos:12357 · issuer key iss:1485 | add | +$28.3M | +89,437 | $118M | $146M | 1,495,290 | 1,584,727 | |
GH RESEARCH PLC ORDINARY SHARESposition key sid:sec:prov:592cbdfa12c811cc697874a89333d4bb · issuer key cusip6:G3855L | trim | +$9.5M | −177,554 | $112M | $122M | 8,827,712 | 8,650,158 | |
PALVELLA THERAPEUTICS INC NE COMposition key sid:sec:prov:306a1219dc3e80453ba2cb392e4281b0 · issuer key cusip6:697947 | add | +$27.8M | +81,980 | $92.0M | $120M | 879,009 | 960,989 | |
ZYMEWORKS INC COMposition key sid:sec:prov:cc436d9af4067ff4382c62284d4ff9e5 · issuer key cusip6:98985Y | trim | −$10.2M | −204,499 | $104M | $93.5M | 3,938,641 | 3,734,142 | |
STOKE THERAPEUTICS INC COMposition key sid:sec:prov:3fee4169345e05a49cf14bcc2babfc71 · issuer key cusip6:86150R | add | +$11.0M | +281,883 | $71.9M | $82.9M | 2,265,674 | 2,547,557 | |
DISC MEDICINE INC COMposition key pos:13022 · issuer key iss:741 | add | +$29.7M | +622,312 | $51.6M | $81.4M | 650,000 | 1,272,312 | |
TYRA BIOSCIENCES INC COMposition key sid:sec:prov:47170149b82e95e4444c881acffa67fc · issuer key cusip6:90240B | trim | +$19.8M | −151,469 | $55.9M | $75.7M | 2,127,665 | 1,976,196 | |
MONTE ROSA THERAPEUTICS INC COMposition key sid:sec:prov:3224bd4d4c1e7dd823e99e6304f866c2 · issuer key cusip6:61225M | add | +$13.2M | +625,000 | $60.1M | $73.4M | 3,835,886 | 4,460,886 | |
ALKERMES PLC SHSposition key pos:16418 · issuer key iss:2418 | new | +$70.7M | +2,000,000 | $0 | $70.7M | — | 2,000,000 | |
KURA ONCOLOGY INC COMposition key sid:sec:prov:44dcd89ab4e3fa904b2bfbfadeb83d25 · issuer key cusip6:50127T | trim | −$20.9M | −171,393 | $89.5M | $68.7M | 8,617,162 | 8,445,769 | |
ANNEXON INC COMposition key sid:sec:prov:45f58e3bf467aafd3516eb30bc85b601 · issuer key cusip6:03589W | trim | +$2.4M | −429,907 | $45.8M | $48.2M | 9,128,080 | 8,698,173 | |
IMMUNOCORE HLDGS PLC ADSposition key pos:16434 · issuer key iss:1166 | trim | −$11.3M | −194,512 | $50.3M | $39.0M | 1,488,975 | 1,294,463 | |
SEPTERNA INC COMposition key sid:sec:prov:c07b19289bd1953ef889bf232426771d · issuer key cusip6:81734D | trim | −$15.5M | −367,533 | $48.0M | $32.5M | 1,720,782 | 1,353,249 | |
SUTRO BIOPHARMA INC COM SHSposition key sid:sec:prov:c4149a9e14976bb08df8d6a0cb6dd6b6 · issuer key cusip6:869367 | new | +$31.2M | +1,251,788 | $0 | $31.2M | — | 1,251,788 | |
FOGHORN THERAPEUTICS INC COMposition key sid:sec:prov:d7ce1f7304a65bd9fa8becb1437c7f71 · issuer key cusip6:344174 | add | −$706K | +540,000 | $28.6M | $27.9M | 5,302,000 | 5,842,000 | |
4D MOLECULAR THERAPEUTICS IN COMposition key sid:sec:prov:adc22e9a1524ab89aa68e69a21eb8d93 · issuer key cusip6:35104E | trim | −$7.9M | −1,750,000 | $34.7M | $26.8M | 4,629,289 | 2,879,289 | |
AVALO THERAPEUTICS INC COM NEWposition key sid:sec:prov:37b91915f07af95197894a79df85a91e · issuer key cusip6:05338F | add | −$233K | +277,588 | $24.6M | $24.4M | 1,355,257 | 1,632,845 | |
ANTERIS TECHNOLOGIES GLOBAL COMposition key sid:sec:prov:0d957017a1f6113a5600ce99517cee7f · issuer key cusip6:03675P | new | +$16.7M | +3,000,000 | $0 | $16.7M | — | 3,000,000 | |
ONKURE THERAPEUTICS INC COM CL Aposition key sid:sec:prov:1b29f8f31311ff2217960a31a2f84a8d · issuer key cusip6:68277Q | new | +$8.2M | +1,978,972 | $0 | $8.2M | — | 1,978,972 | |
TSCAN THERAPEUTICS INC COMposition key sid:sec:prov:39d93878365e006cfbf0af4c0560d7f2 · issuer key cusip6:89854M | add | +$394K | +338,216 | $5.2M | $5.6M | 5,226,074 | 5,564,290 | |
IMAGENEBIO INC COMposition key sid:sec:prov:6db6b47119928ad4af3cf49015c9c5eb · issuer key cusip6:45175G | add | +$15.5K | +307,900 | $5.5M | $5.6M | 802,102 | 1,110,002 | |
| pos:13227 | exit‡e | −$68.5M | −508,031 | $68.5M | $0 | 508,031 | — | |
| pos:13938 | exit‡e | −$8.4M | −45,757 | $8.4M | $0 | 45,757 | — | |
| pos:15762 | exit‡e | −$12.5M | −1,915,000 | $12.5M | $0 | 1,915,000 | — | |
| sid:sec:prov:d05f7035c10c4a84632bc7da6cc6bbcd | exit‡e | −$26.9M | −10,333,600 | $26.9M | $0 | 10,333,600 | — |
9 more changes below.
Mark-to-market only (no share change) · 16
Positions whose share count is identical in both quarters; the value changed with price, not with a decision.
Positionposition matched across quarters by exact reported CUSIP over a registry gap — producer-reconciled identity, never a name match identity_reconciled_by_cusip | Changethe reported share count is unchanged across the pair, so the position reads as held rather than as a buy or a sell; only builds before this release inferred a direction from the reported value instead classified_by_value · "exit" = absent this quarter: disposed, delisted, under confidential treatment, or reported instead by an affiliated manager — the filing does not say which · change not classifiable: value undisclosed on one side of the quarter pair, or neither shares nor value can classify it · "no change" = the share count is identical in both quarters; the value moved only with price, so the row is mark-to-market and never an add or a trim (Add / New / Trim / Exit / No change) · "no prior" = this filer has no comparable holdings list for the previous quarter on record — a first filing under this registration, or a quarter reported inside an affiliated manager's filing — so the position is not called a new stake | Δ valuederived by Public Filings from the published aggregate; NULL means the source did not disclose a usable value — never zero | Δ shares | Prev value | Curr value | Prev shares | Curr shares | Flags |
|---|---|---|---|---|---|---|---|---|
KYMERA THERAPEUTICS INC COMposition key pos:13465 · issuer key iss:1310 | no change | +$30.2M | 0 | $428M | $458M | 5,502,710 | 5,502,710 | |
XENCOR INC COMposition key sid:sec:prov:bc17a1945987420f684d9107b41fd336 · issuer key cusip6:98401F | no change | −$23.2M | 0 | $109M | $86.0M | 7,133,720 | 7,133,720 | |
CULLINAN THERAPEUTICS INC COMposition key pos:13492 · issuer key iss:693 | no change | +$22.2M | 0 | $59.5M | $81.7M | 5,750,683 | 5,750,683 | |
XOMA ROYALTY CORPORATION COM NEWposition key sid:sec:prov:ef90fe6f09df8ace76b72a2a29f3b991 · issuer key cusip6:98419J | no change | +$12.4M | 0 | $68.9M | $81.3M | 2,590,303 | 2,590,303 | |
OLEMA PHARMACEUTICALS INC COMposition key pos:14811 · issuer key iss:1615 | no change | −$53.4M | 0 | $132M | $79.0M | 5,295,893 | 5,295,893 | |
AC IMMUNE SA SHSposition key sid:sec:prov:457173337a7127f576c86a1ee6344121 · issuer key cusip6:H00263 | no change | −$7.7M | 0 | $62.2M | $54.5M | 19,822,436 | 19,822,436 | |
CRESCENT BIOPHARMA INC. COMposition key pos:17611 · issuer key iss:2481 | no change | +$17.9M | 0 | $32.6M | $50.5M | 2,748,763 | 2,748,763 | |
COMPASS THERAPEUTICS INC COMposition key sid:sec:prov:c5f3f37de4d48fd1b29c266e9a76eb0b · issuer key cusip6:20454B | no change | −$621K | 0 | $41.7M | $41.1M | 7,764,842 | 7,764,842 | |
INVIVYD INC COMposition key sid:sec:prov:de0907d604dc0fc94b1a3f8dd009ab9f · issuer key cusip6:00534A | no change | −$22.8M | 0 | $48.2M | $25.4M | 19,525,000 | 19,525,000 | |
ELEDON PHARMACEUTICALS INC COMposition key sid:sec:prov:2e0d559e2cc77fe584e04e6dcaedf54c · issuer key cusip6:28617K | no change | +$9.9M | 0 | $9.5M | $19.4M | 6,293,282 | 6,293,282 | |
X4 PHARMACEUTICALS INC COM NEWposition key sid:sec:prov:19b9675407eb505d5af586b26c66f53a · issuer key cusip6:98420X | no change | +$290K | 0 | $8.9M | $9.2M | 2,233,742 | 2,233,742 | |
IMMUNIC INC COMposition key sid:sec:prov:4629488a5d372449ffa54969c78cc5e4 · issuer key cusip6:4525EP | no change | +$4.4M | 0 | $4.1M | $8.5M | 7,652,972 | 7,652,972 | |
TENAX THERAPEUTICS INC COM NEWposition key sid:sec:prov:9e958f4e10d0d474cc9e75d42ea33a9a · issuer key cusip6:88032L | no change | +$1.3M | 0 | $4.1M | $5.4M | 339,549 | 339,549 | |
MOLECULAR PARTNERS AG ADSposition key sid:sec:prov:43ac1dda87d9c2948d8c04143511cf6d · issuer key cusip6:60853G | no change | −$460K | 0 | $5.8M | $5.4M | 1,353,968 | 1,353,968 | |
INVENTIVA SA ADSposition key sid:sec:prov:36f6260da0bf69546f0e601e6d5bafdc · issuer key cusip6:46124U | no change | +$617K | 0 | $3.2M | $3.8M | 686,040 | 686,040 | |
ENGENE HOLDINGS INC *W EXP 10/31/202position key sid:sec:prov:24163ad406f0b99bb4db4a8f79fb68a7 · issuer key cusip6:29286M | no change | +$85.1K | 0 | $2.4M | $2.5M | 945,402 | 945,402 |
Quarter ended 2026-03-31Newest filing in this build: 2026-07-31. Per-row filing dates are on each receipt.
Changes derive from the aggregate's top-25 slices and keyable positions only; unkeyable holdings are counted in the registry, not differenced. methodology §13F ↗
Book shape
2026-03-31 · concentration · vs tracked median · tick = median- Top-25 concentration
- 92.8%above median 80.0%
- Concentration index
- 583 bpsabove median 446 bps
- Positions with value
- 41 / 41median book 97.5 positions
Concentration uses reported 13F long value, not total assets. The index is withheld when any position lacks a value. Medians are over the 8,748 tracked filers with a 2026-03-31 book; the index median over the 8,662 with a complete book.
null-value positions: 0holdings whose <value> did not parse — retained and counted, never zero-filled · top-N share ·§: 92.8% · HHI (bps) ·§: 583integer Herfindahl–Hirschman index in basis points over disclosed position values · QoQ moves: 45
Filing history
AVAILABLE QUARTERS| Period | Source |
|---|---|
| 2026-03-31 | EDGAR ↗ |
PLANNED sector rotation · Congress overlap · signals for this filer
Complete source filings on SEC EDGAR
The complete filing on EDGAR.
The position list above is served from the published Public Filings build — every position this filer reported for the selected quarter, as it reported it. This block is provenance, not a substitute: the filing itself is the record, and it is one click away. Serving this list is M2-CONTRACT §3, amended 2026-08-02; §3.1 keeps live EDGAR for filings newer than this build.
Open BVF INC/IL's 13F filings on SEC EDGAR ↗Notes on this data
Share changes
Compare consecutive quarters
Position changes retain the producer’s classification and comparability flags. Share counts and reported values describe different changes.
Coverage
A snapshot, not current holdings
Use the quarter selector to inspect available periods. Unknown values stay unknown and each table states its coverage.
ViewPrior quarter not yet availableThis build carries one quarter for this manager: 2026-03-31. Notable managers carry four published quarters, others two.
Reported positions — 2026-03-31
1–41 of 41 positions · $3.1B disclosed value over 41 rows · 0 undisclosed-value rowsEvery row below carries ticker not yet mapped — stated once here rather than repeated on every row.
| KindClassification is not joined into this reported-position view. Use the changed-positions view to compare the two published quarters. | TickerThis list carries reported issuer names and security identities, without a dated ticker mapping. Symbols are not inferred from names. | Issuera position composed from a base filing plus NEW-HOLDINGS amendments keeps every source row here; the composition's latest filed date is the one shown served from this build's published holdings (derived from the filer's own reported rows); every row resolves to its filing | WeightShare of total reported value, calculated only when the full position list has disclosed values. This is 13F long value, not total assets. | Valuevalue undisclosed on the filing: retained and counted, excluded from sums, never shown as $0 | Shares | Position changeShare change is available in the separate comparison view; it is not joined into this position list. | Wt | CongressThe congressional transaction join is unavailable in this build. |
|---|---|---|---|---|---|---|---|---|
| — | KYMRverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | KYMERA THERAPEUTICS INC KYMERA THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $458M | 5,502,710 | — | 14.6% | — | |
| — | — | MOONLAKE IMMUNOTHERAPEUTICS MOONLAKE IMMUNOTHERAPEUTICS · CLASS A ORD CUSIP 61559X104 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $298M | 16,001,284 | — | 9.5% | — | |
| — | RVMDverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | REVOLUTION MEDICINES INC REVOLUTION MEDICINES INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $278M | 2,856,782 | — | 8.9% | — | |
| — | — | NEKTAR THERAPEUTICS NEKTAR THERAPEUTICS · COM NEW CUSIP 640268306 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $184M | 2,559,595 | — | 5.9% | — | |
| — | — | STRUCTURE THERAPEUTICS INC STRUCTURE THERAPEUTICS INC · SPONSORED ADS CUSIP 86366E106 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $167M | 3,459,358 | — | 5.3% | — | |
| — | MIRMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | MIRUM PHARMACEUTICALS INC MIRUM PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $146M | 1,584,727 | — | 4.7% | — | |
| — | — | GH RESEARCH PLC GH RESEARCH PLC · ORDINARY SHARES CUSIP G3855L106 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $122M | 8,650,158 | — | 3.9% | — | |
| — | — | PALVELLA THERAPEUTICS INC NE PALVELLA THERAPEUTICS INC NE · COM CUSIP 697947109 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $120M | 960,989 | — | 3.8% | — | |
| — | — | ZYMEWORKS INC ZYMEWORKS INC · COM CUSIP 98985Y108 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $93.5M | 3,734,142 | — | 3.0% | — | |
| — | — | XENCOR INC XENCOR INC · COM CUSIP 98401F105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $86.0M | 7,133,720 | — | 2.7% | — | |
| — | — | STOKE THERAPEUTICS INC STOKE THERAPEUTICS INC · COM CUSIP 86150R107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $82.9M | 2,547,557 | — | 2.6% | — | |
| — | CGEMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CULLINAN THERAPEUTICS INC CULLINAN THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $81.7M | 5,750,683 | — | 2.6% | — | |
| — | IRONverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | DISC MEDICINE INC DISC MEDICINE INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $81.4M | 1,272,312 | — | 2.6% | — | |
| — | — | XOMA ROYALTY CORPORATION XOMA ROYALTY CORPORATION · COM NEW CUSIP 98419J206 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $81.3M | 2,590,303 | — | 2.6% | — | |
| — | OLMAverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | OLEMA PHARMACEUTICALS INC OLEMA PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $79.0M | 5,295,893 | — | 2.5% | — | |
| — | — | TYRA BIOSCIENCES INC TYRA BIOSCIENCES INC · COM CUSIP 90240B106 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $75.7M | 1,976,196 | — | 2.4% | — | |
| — | — | MONTE ROSA THERAPEUTICS INC MONTE ROSA THERAPEUTICS INC · COM CUSIP 61225M102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $73.4M | 4,460,886 | — | 2.3% | — | |
| — | ALKSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ALKERMES PLC ALKERMES PLC · SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $70.7M | 2,000,000 | — | 2.3% | — | |
| — | — | KURA ONCOLOGY INC KURA ONCOLOGY INC · COM CUSIP 50127T109 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $68.7M | 8,445,769 | — | 2.2% | — | |
| — | — | AC IMMUNE SA AC IMMUNE SA · SHS CUSIP H00263105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $54.5M | 19,822,436 | — | 1.7% | — | |
| — | CBIOverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CRESCENT BIOPHARMA INC. CRESCENT BIOPHARMA INC. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $50.5M | 2,748,763 | — | 1.6% | — | |
| — | — | ANNEXON INC ANNEXON INC · COM CUSIP 03589W102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $48.2M | 8,698,173 | — | 1.5% | — | |
| — | — | COMPASS THERAPEUTICS INC COMPASS THERAPEUTICS INC · COM CUSIP 20454B104 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $41.1M | 7,764,842 | — | 1.3% | — | |
| — | IMCRverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | IMMUNOCORE HLDGS PLC IMMUNOCORE HLDGS PLC · ADS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $39.0M | 1,294,463 | — | 1.2% | — | |
| — | — | SEPTERNA INC SEPTERNA INC · COM CUSIP 81734D104 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $32.5M | 1,353,249 | — | 1.0% | — | |
| — | — | SUTRO BIOPHARMA INC SUTRO BIOPHARMA INC · COM SHS CUSIP 869367201 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $31.2M | 1,251,788 | — | 1.0% | — | |
| — | — | FOGHORN THERAPEUTICS INC FOGHORN THERAPEUTICS INC · COM CUSIP 344174107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $27.9M | 5,842,000 | — | 0.9% | — | |
| — | — | 4D MOLECULAR THERAPEUTICS IN 4D MOLECULAR THERAPEUTICS IN · COM CUSIP 35104E100 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $26.8M | 2,879,289 | — | 0.9% | — | |
| — | — | INVIVYD INC INVIVYD INC · COM CUSIP 00534A102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $25.4M | 19,525,000 | — | 0.8% | — | |
| — | — | AVALO THERAPEUTICS INC AVALO THERAPEUTICS INC · COM NEW CUSIP 05338F306 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $24.4M | 1,632,845 | — | 0.8% | — | |
| — | — | ELEDON PHARMACEUTICALS INC ELEDON PHARMACEUTICALS INC · COM CUSIP 28617K101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $19.4M | 6,293,282 | — | 0.6% | — | |
| — | — | ANTERIS TECHNOLOGIES GLOBAL ANTERIS TECHNOLOGIES GLOBAL · COM CUSIP 03675P102 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $16.7M | 3,000,000 | — | 0.5% | — | |
| — | — | X4 PHARMACEUTICALS INC X4 PHARMACEUTICALS INC · COM NEW CUSIP 98420X202 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $9.2M | 2,233,742 | — | 0.3% | — | |
| — | — | IMMUNIC INC IMMUNIC INC · COM CUSIP 4525EP101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $8.5M | 7,652,972 | — | 0.3% | — | |
| — | — | ONKURE THERAPEUTICS INC ONKURE THERAPEUTICS INC · COM CL A CUSIP 68277Q105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $8.2M | 1,978,972 | — | 0.3% | — | |
| — | — | TSCAN THERAPEUTICS INC TSCAN THERAPEUTICS INC · COM CUSIP 89854M101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $5.6M | 5,564,290 | — | 0.2% | — | |
| — | — | IMAGENEBIO INC IMAGENEBIO INC · COM CUSIP 45175G207 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $5.6M | 1,110,002 | — | 0.2% | — | |
| — | — | TENAX THERAPEUTICS INC TENAX THERAPEUTICS INC · COM NEW CUSIP 88032L605 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $5.4M | 339,549 | — | 0.2% | — | |
| — | — | MOLECULAR PARTNERS AG MOLECULAR PARTNERS AG · ADS CUSIP 60853G106 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $5.4M | 1,353,968 | — | 0.2% | — | |
| — | — | INVENTIVA SA INVENTIVA SA · ADS CUSIP 46124U107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $3.8M | 686,040 | — | 0.1% | — | |
| — | — | ENGENE HOLDINGS INC ENGENE HOLDINGS INC · *W EXP 10/31/202 CUSIP 29286M113 quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.5M | 945,402 | — | 0.1% | — |
1–41 of 41 positions · page 1 of 1
every row this filer reported for the quarter, as it reported it — cross-filer de-duplication is applied to issuer totals elsewhere and never deletes a row here
A 13F is a quarterly, long-only snapshot filed up to 45 days late — not current holdings. what a 13F covers ↗
13F reports cover LONG positions in Section 13(f) securities (US exchange-traded equities plus reportable options, warrants, certain convertibles) held by managers with at least $100M in such securities — so managers below that threshold are absent entirely. No short positions, no cash, no non-13(f) assets — not a full portfolio, and not a census of institutional ownership.
Positions are quarter-end snapshots filed up to 45 days late — not current holdings. A position may have been changed or closed before you ever see it, and is older still by however long ago that quarter ended.
Values are the manager's stated market value at quarter-end in era-dependent units (whole dollars for form versions effective 2023-01-03 onward, thousands before), normalized here to whole dollars with unit_basis carried on every record.
Affiliated managers may report the same position (otherManager), so one position can appear under more than one filer.
Positions under confidential treatment may be omitted until a later amendment discloses them.
These are disclosures, not investment advice (ARCHITECTURE.md §5.2 / M2-CONTRACT §5).